Skip to content Skip to footer
Subscribe Now
Viewpoints_Chris Arendt
VIEWPOINTS

PharmaShots Interview: Takeda’s Chris Arendt Shares Insight on the Data of Alunbrig Presented at ESMO 2021

In an interview with PharmaShots, Chris Arendt, Head of the Oncology Therapeutic Area Unit at Takeda shared his views on the new data of Alunbrig in the P-III ALTA-1L study for the Treatment of ALK+ mNSCLCShots:The P-III ALTA-1L study evaluates Alunbrig vs Crizotinib in patients with ALK+ mNSCLC who have not received prior treatment with an ALK inhibitorThe results showed…
November 22, 2021

Read more

Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021.Shots:Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021

Read more

Viewpoints_Ying Huang
VIEWPOINTS

PharmaShots Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel

In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends' collaboration with Janssen.Shots:The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were recently presented at the 62nd ASH MeetingThe…
February 25, 2021

Read more

Viewpoints_Mathew L. Sherman
VIEWPOINTS

PharmaShots Interview: Deciphera’s Mathew L. Sherman Shares Insight on Data of QINLOCK and DCC-3014 Presented at CTOS 2020

In an interview with PharmaShots, Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera shed light on encouraging preliminary results from the ongoing P-I/II study of DCC-3014 in TGCT patients and also presented the data of QINLOCK at CTOS 2020Shots:Deciphera presented encouraging preliminary results from the ongoing Phase 1/2 study of DCC-3014 in tenosynovial giant cell tumor…
February 17, 2021

Read more

Viewpoint_Andrew_Greenspan_2021
VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insights on the Data Presented at ACR2020

In a recent interview with PharmaShots, Andrew Greenspan, MD, VP Medical Affairs of Janssen Immunology shared his views on Janssen's commitment to advance research in rheumatic disease.Shots:Janssen presented clinical trial results in 35 abstracts featuring findings across PsA, RA, and SLE at ACR Convergence 2020 Virtual Scientific ProgramSixteen abstracts focus on Tremfya in adults…
January 11, 2021

Read more

Viewpoint_Kimberly_Smith_2020
VIEWPOINTS

PharmaShots Interview: ViiV Healthcare’s Kimberly Smith Shares Insight on Data of Long-Acting Cabotegravir and Rilpivirine Presented at IDWeek 2020

In a recent interview with PharmaShots, Kimberly Smith, MD, MPH, Head of Research & Development at ViiV Healthcare shared information on the positive findings presented at the 2020 Infectious Diseases Society of America (IDWeek) and the impact of COVID-19 on the development of long-acting cabotegravir and rilpivirine.Shots:The company reported the positive findings of a pooled…
December 28, 2020

Read more